SciTech-Service Oy Celebrates 42 Years of Establishing Innovation in the Bioeconomy Transition
SciTech-Service Oy proudly marks its 42nd anniversary, celebrating over four decades of innovative work at the convergence of science and sustainable technology. Since 1983, this Finland-based firm has been leading in interpreting scientific knowledge into practical eco-conscious solutions that support industries in their shift from fossil-based to bio-based materials. Under the leadership of CEO Dr. Eric Enqvist, the company continues with its clear mission of supporting client innovation by developing process concepts. Filtration Testing at SciTech's Laboratory - Rauma, Finland
"We are helping mankind to find a travelable way to a circular bioeconomy," says Dr. Enqvist. "Technology, for us, is the application of scientific knowledge for business purposes. We don't just conduct experiments, we create the missing pieces that allow ideas to become practical and scalable solutions."
From its beginnings in the pulp and paper industry to today's advanced focus on cellulosic textiles and bio-based chemicals, SciTech has consistently anticipated and adapted to the global shift in industrial needs. The company's strength lies in its deep understanding of wood chemistry, material science, and process engineering, enabling it to offer custom process concepts that bridge the gap between theoretical science and commercial application.
An innovative process for producing wood pulp was one of SciTech's earliest innovations, which now supports the production of millions of tons of pulp annually. This demonstrates the company's ability to turn in-house scientific ideas into impactful, globally adopted technologies and to serve industries worldwide.
Today, with two modern laboratories in Helsinki and Rauma, SciTech offers a wide range of services, from biomass fractionation to pulp and paper tests and pilot trials for industrial textile fiber production. These labs play a critical role in providing clients with high-value data while avoiding costly and time-consuming full-scale R&D programs. Instead, SciTech focuses only on essential experiments, making the company a cost-effective yet high-impact partner in innovation.
SciTech has consistently outperformed expectations despite its small employee size, often impressing clients. The company has been highly successful in building and evolving its team of experts. The key strength lies in their integrated expertise in chemistry, physics, and process engineering, and in their openness to exploring undiscovered territory.
"We are comfortable working with the unexplored factors," Dr. Enqvist explains. "Our process concepts are based on rigorous modeling, mass balances, heat balances, and chemical cycles, so we can present multiple technical options to our clients. They can then choose the most feasible option based on realistic projections." SciTech's work now spans creating a diversified portfolio that supports a range of bio-based industries from developing novel solutions to supporting mill operations.
Pilot Equipment SciTech's Laboratory - Rauma, Finland
In 2023, SciTech was acquired by the international technology group ANDRITZ, a move that has significantly enhanced its global reach and operational stability. Importantly, SciTech continues to operate independently, preserving the integrity of its client relationships and its neutral, confidential consulting model.
According to Director Heikki Hassi, "Becoming an independent part of the ANDRITZ gives SciTech firm ground for further development. The bioeconomy is evolving rapidly, and staying ahead means combining deep scientific knowledge with bold investments."
Looking forward, SciTech-Service Oy remains committed to expanding its impact. With the world yet to fully transition from fossil to bio-based economies, Dr. Enqvist believes there is still much work to be done. He says, "We will continue on this journey of helping industries make that shift, step by step, with science as the roadmap."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
6 hours ago
- Int'l Business Times
Musk Shocks Tesla Staff After Asking If Trump's Tariffs Were Affecting His Company: Report
Following the end of his temporary stint in government, billionaire Trump supporter Elon Musk has returned to his tech empire, surprising his own staff by inquiring about the impact of Trump tariffs upon his businesses. Though Musk's visits to Tesla offices and factories diminished following President Donald Trump's inauguration, he did visit one of his company's offices in Palo Alto, California, just days before an earnings call in April, according to the New York Times. He asked about how tariffs enacted by his presidential ally had impacted his company, and was briefed on supply chain weaknesses and subsequent effects upon Tesla. Some attendees of the meeting became concerned by the timing of Musk's inquiries, with Trump having announced the intended implementation of tariffs in February. Just days after the meeting, Tesla profits dropped to the lowest level they had been at in four years after vehicle sales fell 13 percent in the first quarter. According to California-based Tesla salesman Matthew LaBrot, it had become "a grind every day to sell a car when that did not used to be the case." Though Musk stated that he was not in favor of high or unpredictable tariffs in April, he followed this sentiment by adding that any decision on the implementation of tariffs "is entirely up to the president of the United States." During Tesla's first quarter earnings call in April, Musk stated that "if some country is doing something predatory with tariffs," or "if a government is providing extreme financial support for a particular industry, then you have to do something to counteract that." "He will listen to my advice. But then it's up to him, of course, to make his decision," Musk said of Trump. "I've been on the record many times saying that I believe lower tariffs are generally a good idea." Musk's time as a member of the Trump administration came to an end in May. "Elon is really not leaving," Trump told reporters in the Oval Office. "He's going to be back and forth. I think I have a feeling it's his baby, and I think he's going to be doing a lot of things." Originally published on Latin Times
Int'l Business Times
7 hours ago
- Int'l Business Times
AI Startup Backed by Microsoft Revealed to Be 700 Indian Employees Pretending to Be Chatbots
A once-hyped AI startup backed by Microsoft has filed for bankruptcy after it was revealed that its so-called artificial intelligence was actually hundreds of human workers in India pretending to be chatbots. a London-based company previously valued at $1.5 billion, marketed its platform as an AI-powered solution that made building apps as simple as ordering pizza. Its virtual assistant, "Natasha," was supposed to generate software using artificial intelligence. In reality, nearly 700 engineers in India were manually coding customer requests behind the scenes, the Times of India reported. The ruse began to collapse in May when lender Viola Credit seized $37 million from the company's accounts, uncovering that had inflated its 2024 revenue projections by 300%. An audit revealed the company generated just $50 million in revenue, far below the $220 million it claimed to investors. A Wall Street Journal report from 2019 had already questioned AI claims, and a former executive sued the company that same year for allegedly misleading investors and overstating its technical capabilities. Despite that, the company raised over $445 million from big names including Microsoft and the Qatar Investment Authority. collapse has triggered a federal investigation in the U.S., with prosecutors in New York requesting financial documents and customer records. Founder Sachin Dev Duggal stepped down earlier this year and was replaced by Manpreet Ratia, who reportedly uncovered the company's internal misrepresentations. The company now owes millions to Amazon and Microsoft in cloud computing costs and has laid off around 1,000 employees. On LinkedIn , the company announced its entry into insolvency proceedings, citing "historic challenges and past decisions" that strained its finances. The fallout is seen as one of the biggest failures of the post-ChatGPT AI investment boom and has renewed scrutiny of "AI washing"—the trend of rebranding manual services as artificial intelligence to secure funding. Originally published on Latin Times
Int'l Business Times
2 days ago
- Int'l Business Times
Saudi Arabia Advances Cancer Care with Potential Approval of Multikine Immunotherapy
In a pivotal development in cancer care, Saudi Arabia may become the first country in the world to approve CEL-SCI Corporation 's investigational immunotherapy, Multikine, for commercial use in treating head and neck cancer. The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine available to patients as early as this summer. This move comes after favorable engagement between CEL-SCI and SFDA reviewers announced in April of this year, positioning Saudi Arabia at the forefront of global innovation in oncology. If approved, Multikine would represent a new era in immuno-oncology by becoming the first neoadjuvant (pre-surgical) immunotherapy available for advanced primary head and neck cancer. The Unmet Need in Head and Neck Cancer Head and neck cancers (HNCs) account for 5% of all cancer cases in Saudi Arabia, which is around 650–700 new cases every year. Mostly affecting men attributed to tobacco use, including cigarettes, shisha, and smokeless tobacco like shamma . In the southern provinces like Jazan, shamma use is linked to high oral cancer rates, including among women. Head and neck cancers are often diagnosed at advanced stages, with 80% or more of patients having lymph node involvement at diagnosis. The most common subtypes in the Kingdom are oral cavity and nasopharyngeal carcinomas. Despite advances in surgery and radiation, 5-year survival rates have plateaued at 50%, so there is a big need for more effective first-line treatment options. The Science Behind Multikine Multikine (Leukocyte Interleukin, Injection) is a unique immunotherapeutic biologic composed of a carefully calibrated mix of natural cytokines derived from activated human white blood cells. Unlike checkpoint inhibitors used in later-stage cancers, Multikine is designed to be administered before surgery, while the patient's immune system is still intact and the tumor is present as a target. In CEL-SCI's global Phase III trial , the largest ever conducted in head and neck cancer, Multikine demonstrated a statistically significant improvement in five-year survival rates for a defined patient subgroup: those treated with surgery followed by radiation but not chemotherapy. Among these patients, five-year survival improved from 48.6% to 62.7%, effectively cutting the risk of death nearly in half. Multikine also showed strong safety results, with no late toxicities reported and notable improvements in patient-reported quality of life. Some patients experienced complete tumor regression before surgery, supporting the idea that Multikine may sensitize tumors to subsequent standard treatments. Alignment with Saudi Vision 2030 The approval of Multikine fits perfectly into Saudi Vision 2030 , the national framework for economic diversification and innovation that includes transforming the healthcare and biotech sectors. Central to this transformation is the localization of pharmaceutical manufacturing, attracting clinical research, and becoming a regional hub for medical innovation. The SFDA's Breakthrough Medicine Designation, modeled after similar programs in the U.S. and EU, is a direct byproduct of this strategy. It aims to expedite the approval of therapies that show significant clinical promise in addressing unmet medical needs. By targeting a cancer type with limited first-line advancements, Multikine qualifies as a prime candidate for such accelerated evaluation. Saudi Arabia has also shown leadership in adopting advanced oncology treatments. The country recently became the first in the region to manufacture CAR-T cell therapies domestically, reducing costs and access times for blood cancer patients. The addition of Multikine would continue this trend of delivering next-generation therapeutics within the Kingdom. Oncology Infrastructure Ready for Innovation Saudi Arabia's oncology infrastructure has matured significantly over the last decade. Institutions like King Faisal Specialist Hospital & Research Centre (KFSHRC), King Fahad Medical City (KFMC), and Princess Noorah Oncology Center are now equipped with the latest technologies, including proton therapy and precision diagnostics. These institutions routinely adopt new cancer treatments and maintain specialized head and neck cancer teams composed of ENT surgeons, radiation oncologists, medical oncologists, and rehabilitation professionals. The availability of multidisciplinary tumor boards and growing use of tele-oncology services further support the clinical integration of innovative therapies like Multikine. The Ministry of Health's e-Platform for oncology consultations ensures that even patients in remote regions can access national expertise, which is an essential element as the country decentralizes specialist care under the Vision 2030 framework. Regional and Global Impact If Saudi Arabia approves Multikine in 2025, it will not only be a therapeutic breakthrough for patients but also a model for fast-tracking drug development in the MENA region. CEL-SCI has already announced plans to partner with a local manufacturer in the Kingdom to supply Multikine across the Middle East and North Africa. The implications go beyond geography. An early Saudi approval will strengthen CEL-SCI's case for conditional approvals in other jurisdictions, including Canada and the EU, where the company has filed parallel regulatory submissions. What's Ahead Multikine's journey of over a decade of clinical development is the potential of immunotherapy to improve survival in areas where there are few options. Saudi Arabia's regulatory and clinical leadership may now be the launchpad for this innovation. For patients newly diagnosed with head and neck cancer in the Kingdom, this means more than hope. It soon means potential access.
